⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRMD News
CorMedix Inc.
Mundipharma gibt positive vorläufige Ergebnisse der Phase-III-Studie ReSPECT bekannt, in der ▼ REZZAYO ® (Rezafungin) zur Prophylaxe invasiver Pilzerkrankungen nach einer allogenen hämatopoetischen Stammzelltransplantation untersucht wurde
businesswire.com
CRMD
Mundipharma宣布评估用于预防异基因造血干细胞移植患者侵袭性真菌病的 ▼ REZZAYO ® （雷扎芬净）的三期ReSPECT临床试验取得积极总体结果
businesswire.com
CRMD
Mundipharma anuncia resultados positivos preliminares del estudio de Fase III ReSPECT que evalúa ▼ REZZAYO ® (rezafungina) para la profilaxis de enfermedades fúngicas invasivas en pacientes sometidos a trasplante...
businesswire.com
CRMD
Mundipharma annonce les premiers résultats positifs de l’essai de phase III ReSPECT évaluant ▼ REZZAYO ® (rézafungine) dans la prophylaxie des infections fongiques invasives chez les patients ayant subi une greffe allogénique...
businesswire.com
CRMD
Mundipharma宣布，其評估 REZZAYO ® （雷扎芬淨）用於預防異基因造血幹細胞移植患者侵襲性真菌病的III期ReSPECT試驗取得正面頂線結果
businesswire.com
CRMD
Form 8-K
sec.gov
CRMD
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
businesswire.com
CRMD
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
globenewswire.com
CRMD
CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
prnewswire.com
CRMD
CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
prnewswire.com
CRMD